GSK (LSE:GSK) secured Chinese approval for Exdensur for severe asthma patients aged 12 and older. The company also had its ...
GSK (LSE:GSK) has received FDA approval for Lynavoy (linerixibat), the first treatment in the US for cholestatic pruritus in ...
Learn about the GSK IMPACT Awards winners in 2026 and how they are making a significant impact on their communities.
GSK (GSK.L) on Monday unveiled regulatory updates for its drug portfolio in China, with its asthma medication Exdensur approved and its chronic hepatitis B treatment bepirovirsen accepted for review.
GlaxoSmithKline ( (GB:GSK) ) just unveiled an announcement.
Pharma giant GSK (NYSE:GSK) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Pharma giant GSK (NYSE:GSK) ...
Samsung Biologics, the biotech arm of Samsung Group, said Wednesday it has acquired a U.S. manufacturing facility from ...
Stakeholders responding to recent draft guidance from the US Food and Drug Administration (FDA) on the use of minimal ...
GSK’s Exdensur receives China NMPA approval for the treatment of severe asthma: London, UK Tuesday, March 31, 2026, 09:00 Hrs [IST] GSK plc, a global biopharma company, announce ...
Samsung Biologics finalized the acquisition of GSK's biopharmaceutical manufacturing facility in Rockville, Maryland, ...
(Alliance News) - GSK PLC on Monday reported regulatory momentum in China for its drugs Exdensur and bepirovirsen. The pharmaceutical firm's shares were up 0.5% to 2,060.00 pence on Monday morning in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results